Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

Zeuzem, Stefan; Dusheiko, Geoffrey; Salupere, Riina; Mangia, Alessandra; Flisiak, Robert; H. Hyland, Robert; Illeperuma, Ari; S. Svarovskaia, Evguenia; M. Brainard, Diana; T. Symonds, William; Mani Subramanian, G.; G. McHutchison, John; Weiland, Ola; W. Reesink, Hendrik; Ferenci, Péter; Hézode, Christophe; Esteban, Rafael

doi:10.1056/nejmoa1316145

Public

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

Published in New England Journal of Medicine • May 4, 2014

Authors:

Stefan Zeuzem

Geoffrey Dusheiko

Riina Salupere

Abstract

BACKGROUND: In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV ...

Subject

Sofosbuvir

Ribavirin

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!